Physician profile
Nathan Ritter
NPI 1417095076
$2,272.81
in general payments reported to CMS, 2019-2025
16 companies · $774 in 2025
The $774 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.62 · 2022: $18.42 · 2023: $849 · 2024: $600 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,206 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,205.51 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $403.77 | 2022-2025 | |
| Boston Scientific Corporation | $359.66 | 2023-2025 | Watchman, Watchman Access System, Watchman Flx |
| Amgen INC. | $299.95 | 2023-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.28 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $182.69 | 2023-2025 | Farxiga, Wainua |
| Scpharmaceuticals INC. | $150.64 | 2023 | |
| Alnylam Pharmaceuticals INC. | $126.74 | 2025 | Amvuttra, Onpattro |
| Novo Nordisk INC | $118.65 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $94.09 | 2023-2024 | Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $72.89 | 2023-2025 | Camzyos |
| Irhythm Technologies, INC. | $53.35 | 2021-2023 | Zio Xt Patch |
| Pfizer INC. | $48.39 | 2024-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $20.82 | 2023 | Arcalyst |
| Janssen Pharmaceuticals, INC | $20.75 | 2023 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $18.10 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.04 | 2025 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Ritter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.